1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,111 | 0,130 | 12:43 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| CANTARGIA Aktie jetzt für 0€ handeln | |||||
| 01.04. | Cantargia appoints Morten Lind Jensen as Chief Medical Officer | 170 | ACCESS Newswire | LUNDE, SE / ACCESS Newswire / April 1, 2025 / Cantargia (STO:CANTA) - Cantargia AB (publ) ("Cantargia") (Nasdaq Stockholm:CANTA) today announced the appointment of Morten Lind Jensen, MD, PhD, as Chief... ► Artikel lesen | |
| 25.03. | Cantargia Publishes An Abstract On Parallel Anti-Tumor Activity And Reduction Of Chemotherapy-Induced Neuropathy With Nadunolimab | 399 | ACCESS Newswire | LUND, SWEDEN / ACCESS Newswire / March 25, 2025 / Cantargia (STO:CANTA)Nadunolimab's additional potential in mitigating neuropathy demonstrated by data from Cantargia's CESTAFOUR and CAPAFOUR clinical... ► Artikel lesen | |
| 25.03. | Cantargia Presents Promising Preclinical Results on a Novel IL1RAP-Targeting Antibody-Drug Conjugate at AACR 2025 | 271 | ACCESS Newswire | LUND, SE / ACCESS Newswire / March 25, 2025 / Cantargia (STO:CANTA) Cantargia (Cantargia AB (publ); Nasdaq Stockholm:CANTA) today announced an upcoming presentation of preclinical data on the development... ► Artikel lesen | |
| 13.03. | Cantargia to Participate at Van Lanschot Kempen's Life Sciences Conference | 270 | ACCESS Newswire | LUND, SE / ACCESS Newswire / March 13, 2025 / Cantargia (STO:CANTA) Cantargia AB (publ) ("Cantargia") (Nasdaq Stockholm: CANTA) today announced that members of Cantargia's management will participate... ► Artikel lesen | |
| 12.03. | Cantargia (OMX: CANTA) enrols first patient in leukaemia study | 231 | Edison Investment Research | Cantargia has confirmed that the first patient has been in enrolled in the study assessing nadunolimab in leukaemia. More specifically, this is an investigator-initiated, open-label, Phase Ib/IIa clinical... ► Artikel lesen | |
| 12.03. | First Patient Enrolled in Cantargia's Leukemia Study with nadunolimab | 385 | ACCESS Newswire | LUND, SE / ACCESS Newswire / March 12, 2025 / Cantargia (STO:CANTA)Open label study in forty AML and MDS patientsStudy financed by the US Department of DefenseCantargia (Cantargia AB; Nasdaq Stockholm:CANTA)... ► Artikel lesen | |
| 10.03. | Cantargia (OMX: CANTA) breast cancer study fully recruited | 252 | Edison Investment Research | Cantargia has announced that it has completed recruiting patients (n=102) for the randomised Phase II TRIFOUR trial, which is evaluating nadunolimab in combination with platinum-based chemotherapy,... ► Artikel lesen | |
| 10.03. | Cantargia's TRIFOUR Phase 2 Study Investigating Nadunolimab in Triple Negative Breast Cancer Fully Recruited | 233 | ACCESS Newswire | TRIFOUR is Cantargia's first randomized, controlled study of nadunolimabFirst preliminary efficacy results expected mid-2025 LUND, SWEDEN / ACCESS Newswire / March 10, 2025 / Cantargia (Cantargia AB)... ► Artikel lesen | |
| 06.03. | Cantargia to Participate at H.C. Wainwright's Annual Autoimmune & Inflammatory Virtual Conference | 202 | ACCESS Newswire | LUND, SE / ACCESS Newswire / March 6, 2025 / Cantargia (STO:CANTA) Cantargia AB (publ) ("Cantargia") (Nasdaq Stockholm: CANTA) today announced that Damian Marron, Interim CEO, will participate at the... ► Artikel lesen | |
| 05.03. | Cantargia (OMX: CANTA) reports positive CAN10 update | 242 | Edison Investment Research | Cantargia has reported encouraging pharmacokinetic data from the first cohort in the multiple ascending dose portion of the CAN10 study. Importantly, the data align with the single dose portion of the... ► Artikel lesen | |
| 05.03. | Cantargia Reports Promising CAN10 Phase 1 Data From First Multiple Dose Cohort, and FDA and Key Opinion Leader Feedback | 239 | ACCESS Newswire | LUND, SE / ACCESS Newswire / March 5, 2025 / Cantargia (STO:CANTA)Promising multiple dose PK data continue to support 4-weekly dosingFDA advice received supporting phase 2 design in HSStrong Key Opinion... ► Artikel lesen | |
| 21.02. | Cantargia Publishes Full Year Report for 2024 | 263 | ACCESS Newswire | LUND, SWEDEN / ACCESS Newswire / February 21, 2025 / Cantargia (STO:CANTA) Cantargia AB's (publ) ("Cantargia") (Nasdaq Stockholm:CANTA) full year report for 2024 is now available on the company's web... ► Artikel lesen | |
| 19.02. | Cantargia to Participate in Leerink Partners Global Healthcare Conference | 239 | ACCESS Newswire | LUND, SE / ACCESS Newswire / February 19, 2025 / Cantargia AB (publ) ("Cantargia") (Nasdaq Stockholm:CANTA) today announced that members of Cantargia's management will participate in one-on-one meetings... ► Artikel lesen | |
| 13.02. | Invitation to Presentation of Cantargia's Year-End Report 2024 | 183 | ACCESS Newswire | LUND, SE / ACCESSWIRE / February 13, 2025 / Cantargia (STO:CANTA) Cantargia (Cantargia AB; Nasdaq Stockholm: CANTA) invites investors, analysts and the press to a presentation of the interim October... ► Artikel lesen | |
| 05.02. | Cantargia Announces Management Changes | 314 | ACCESS Newswire | Göran Forsberg, CEO, steps downDamian Marron, Board Director, to assume role of Interim CEORecruitment process for new permanent CEO underway LUND, SWEDEN / ACCESS Newswire / February 5, 2025 / Cantargia... ► Artikel lesen | |
| 31.01. | Cantargia Announces Changes in Number of Shares and Votes | 243 | ACCESS Newswire | LUND, SWEDEN / ACCESS Newswire / January 31, 2025 / Cantargia AB's (publ) ("Cantargia" or the "Company") (Nasdaq Stockholm:CANTA) today announced that the number of shares and votes in Cantargia AB... ► Artikel lesen | |
| 18.12.24 | Cantargia Publishes Strong Preclinical Effects and Clinical Monotherapy Results on Nadunolimab in Pancreatic Cancer in Journal for Immunotherapy of Cancer | 348 | ACCESS Newswire | LUND, SE / ACCESSWIRE / December 18, 2024 / Cantargia (STO:CANTA) Cantargia (Cantargia AB; Nasdaq Stockholm: CANTA) today announced the publication of preclinical and clinical results using the IL1RAP... ► Artikel lesen | |
| 11.12.24 | Cantargia and GEICAM Present Updated Phase 1 Clinical Data and New Translational Results on Nadunolimab Treatment in Advanced Triple Negative Breast Cancer at San Antonio Breast Cancer Symposium | 384 | ACCESS Newswire | LUND, SWEDEN / ACCESSWIRE / December 11, 2024 / Cantargia (STO:CANTA) Cantargia (Cantargia AB; Nasdaq Stockholm:CANTA) today reported updated results from the phase 1b study in 15 advanced triple negative... ► Artikel lesen | |
| 02.12.24 | Extraordinary General Meeting in Cantargia AB | 225 | ACCESS Newswire | LUND, SE / ACCESSWIRE / December 02, 2024 / Cantargia (STO:CANTA) Cantargia's extraordinary general meeting on December 2, 2024, resolved to approve the board's resolution from November 6, 2024 to increase... ► Artikel lesen | |
| 02.12.24 | Cantargia AB: Extraordinary general meeting in Cantargia AB (publ) | 325 | GlobeNewswire (Europe) | Cantargia's extraordinary general meeting on December 2, 2024, resolved to approve the board's resolution from November 6, 2024 to increase the company's share capital through the issuance of new shares... ► Artikel lesen |
Seite:
1 2 3 Weiter >>
48 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 82,95 | +7,80 % | BioNTech-Aktie: Das tragische Ende! | News von Trading-Treff.de Für die BioNTech sieht es nach einem tragischen Ende des Aufwärtsmarsches aus. Die Mainzer haben auch am Donnerstag einen Abschlag in Höhe von mehr als -1,9 % hinnehmen müssen.... ► Artikel lesen | |
| EVOTEC | 5,690 | +6,95 % | Aktie vor 100 %-Rally! Evotec, thyssenkrupp, Vidac Pharma Aktie vor goldenem April? | Können sich Aktionäre bald über 100 % Kursgewinn freuen? Geht es nach Analysten, könnte dies bei Evotec bevorstehen. Allerdings müssen Aktionäre zuvor einen wichtigen Termin im April markieren. Dort... ► Artikel lesen | |
| QIAGEN | 36,395 | +2,39 % | EQS-Adhoc: QIAGEN N.V.: QIAGEN kündigt starkes vorläufiges Ergebnis im ersten Quartal 2025 an und hebt die Prognose für den bereinigten Gewinn je Aktie für das Gesamtjahr 2025 | EQS-Ad-hoc: QIAGEN N.V. / Schlagwort(e): Vorläufiges Ergebnis
QIAGEN N.V.: QIAGEN kündigt starkes vorläufiges Ergebnis im ersten Quartal 2025 an und hebt die Prognose für den bereinigten Gewinn... ► Artikel lesen | |
| REGENERON PHARMACEUTICALS | 517,80 | -1,75 % | Regeneron Aktie: Sie steht unter Druck! | Das Biotech-Unternehmen verzeichnet einen massiven Wertverlust von über 28% im letzten Monat, während Analysten weiterhin ein Kurspotenzial von mehr als 60% prognostizieren. Die Regeneron Pharmaceuticals... ► Artikel lesen | |
| BRAIN BIOTECH | 2,310 | -1,28 % | EQS-News: BRAIN Biotech AG: Ergebnisse der Hauptversammlung 2025 zum Finanzjahr 2023/24 der BRAIN Biotech AG | EQS-News: BRAIN Biotech AG
/ Schlagwort(e): Hauptversammlung
Ergebnisse der Hauptversammlung 2025 zum Finanzjahr 2023/24 der BRAIN Biotech AG
18.03.2025 / 16:45 CET/CEST
Für... ► Artikel lesen | |
| SCORPIUS | 0,122 | 0,00 % | XFRA 1HB0: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILSCORP.HLDGS.NEW... ► Artikel lesen | |
| CARDIOL THERAPEUTICS | 0,784 | +5,95 % | H.C. Wainwright maintains $9 target on Cardiol Therapeutics stock | ||
| BURCON NUTRASCIENCE | 0,050 | +0,40 % | Burcon NutraScience Corporation: Burcon Integrates Protein Technologies at Galesburg Facility | Vancouver, British Columbia--(Newsfile Corp. - April 1, 2025) - Burcon NutraScience Corporation (TSX: BU) (OTCQB: BRCNF) ("Burcon" or the "Company"), a global technology leader in the development of... ► Artikel lesen | |
| CSL | 135,08 | -2,20 % | CSL LIMITED: Notification of cessation of securities - CSL | ||
| MANNKIND | 4,267 | -0,61 % | Mizuho sets MannKind stock Outperform with $12 target | ||
| OXFORD NANOPORE TECHNOLOGIES | 1,370 | +3,63 % | Cepheid and Oxford Nanopore Technologies Partner to Advance Automated Sequencing-Based Solutions | Collaboration to leverage Oxford Nanopore's sequencing platform and Cepheid's GeneXpert system to advance the field of sequencing for infectious diseases
OXFORD, United Kingdom and... ► Artikel lesen | |
| OCULAR THERAPEUTIX | 5,326 | -14,92 % | Expert Outlook: Ocular Therapeutix Through The Eyes Of 5 Analysts | ||
| ADAPTIMMUNE THERAPEUTICS | 0,214 | +0,94 % | Adaptimmune Therapeutics PLC: Adaptimmune Provides Q4 and Full Year 2024 Business Update | TECELRA® launch momentum accelerating - 10 patients apheresed in Q1 2025 and 3 in 2024; 20 ATCs available; all manufacturing and supply goals achievedLete-cel on track to initiate rolling BLA submission... ► Artikel lesen | |
| CODEXIS | 2,166 | +2,27 % | CODEXIS, INC. - 8-K, Current Report | ||
| TELO GENOMICS | 0,035 | +2,94 % | Telo Genomics Corp.: Telo Genomics Announces Appointment of John Farlinger to Its Board of Directors | Toronto, Ontario--(Newsfile Corp. - April 4, 2025) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo Genomics") a leader in the development of diagnostic and prognostic tests... ► Artikel lesen |
Das Unternehmen CANTARGIA AB kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von +0,002 (+2,41 %) liegt der Kurs bei 0,089 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CANTARGIA AB finden Sie auf Wallstreet Online.
